Janice P. Dutcher

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler et al. · Journal of Clinical Oncology · 2004 · 943 citations · Full text

Pharmacy, Oncology, Pharmacology +16

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg et al. · Journal of Clinical Oncology · 2008 · 908 citations · Full text

Medicine, Oncology, Pharmacology +10

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

David F. McDermott, Meredith M. Regan, Joseph I. Clark et al. · Journal of Clinical Oncology · 2004 · 819 citations

Medicine, Oncology, Pharmacotherapy +15

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

John P. Leonard, Matthew L. Sherman, Gerald L. Fisher et al. · PubMed · 1997 · 814 citations

Pharmacy, Immunology, Toxicology +16

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Naomi B. Haas, Judith Manola, Robert G. Uzzo et al. · The Lancet · 2016 · 638 citations

Medicine, Oncology, Pharmacology +14